Alucio - #aluciosf monthly Product Advisory Board Spotlight focuses on Nika Sajed: I'm a trained pharmacist but currently work as a medical scientist for HIV treatment. What I love most about my
![Sajed Sbeih to Take Over as Managing Director Commercial Operations for General Motors Africa and Middle East Sajed Sbeih to Take Over as Managing Director Commercial Operations for General Motors Africa and Middle East](https://media.gm.com/dld/content/Pages/news/me/en/2020/gm/08-26-TSajed-Sbeih-to-Take-Over-as-Managing-Director-Commercial-Operations-for-General-Motors-Africa-and-Middle-East/jcr:content/image.resize.jpg/1642015800221.jpg)
Sajed Sbeih to Take Over as Managing Director Commercial Operations for General Motors Africa and Middle East
![Frontiers | Escherichia coli ST302: Genomic Analysis of Virulence Potential and Antimicrobial Resistance Mediated by Mobile Genetic Elements | Microbiology Frontiers | Escherichia coli ST302: Genomic Analysis of Virulence Potential and Antimicrobial Resistance Mediated by Mobile Genetic Elements | Microbiology](https://www.frontiersin.org/files/Articles/496696/fmicb-10-03098-HTML-r1/image_m/fmicb-10-03098-g001.jpg)
Frontiers | Escherichia coli ST302: Genomic Analysis of Virulence Potential and Antimicrobial Resistance Mediated by Mobile Genetic Elements | Microbiology
![Frontiers | Escherichia coli ST302: Genomic Analysis of Virulence Potential and Antimicrobial Resistance Mediated by Mobile Genetic Elements | Microbiology Frontiers | Escherichia coli ST302: Genomic Analysis of Virulence Potential and Antimicrobial Resistance Mediated by Mobile Genetic Elements | Microbiology](https://www.frontiersin.org/files/Articles/496696/fmicb-10-03098-HTML-r1/image_m/fmicb-10-03098-g009.jpg)
Frontiers | Escherichia coli ST302: Genomic Analysis of Virulence Potential and Antimicrobial Resistance Mediated by Mobile Genetic Elements | Microbiology
![PDF) Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies PDF) Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies](https://i1.rgstatic.net/publication/323107466_Sofosbuvir-Based_Direct-Acting_Antiviral_Therapies_for_HCV_in_People_Receiving_Opioid_Substitution_Therapy_An_Analysis_of_Phase_3_Studies/links/5a7f8a190f7e9be137c73488/largepreview.png)